Scott Lish Sells 23,183 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 23,183 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $12.03, for a total value of $278,891.49. Following the completion of the sale, the chief operating officer now owns 844,494 shares in the company, valued at $10,159,262.82. This represents a 2.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Scott Lish also recently made the following trade(s):

• On Thursday, February 6th, Scott Lish sold 27,453 shares of Alphatec stock. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97.

Alphatec Price Performance

Alphatec stock opened at $12.53 on Friday. The business has a 50-day simple moving average of $10.70 and a 200 day simple moving average of $8.42. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $14.88. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -9.79 and a beta of 1.43. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. On average, research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on ATEC shares. Barclays raised their price objective on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price target on shares of Alphatec in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a report on Friday. Finally, Piper Sandler lifted their target price on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.67.

Institutional Trading of Alphatec

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. Vanguard Group Inc. increased its stake in Alphatec by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company’s stock valued at $54,795,000 after acquiring an additional 47,797 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Alphatec by 36.5% in the 4th quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company’s stock worth $45,800,000 after purchasing an additional 1,334,780 shares in the last quarter. Royal Bank of Canada increased its position in shares of Alphatec by 171.2% during the 4th quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company’s stock valued at $29,240,000 after purchasing an additional 2,010,806 shares during the last quarter. State Street Corp increased its position in shares of Alphatec by 10.1% during the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock valued at $17,453,000 after purchasing an additional 287,350 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Alphatec by 11.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after buying an additional 297,850 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.